tradingkey.logo

Transmedics Group Inc

TMDX
查看詳細走勢圖
127.670USD
+6.600+5.45%
收盤 12/19, 16:00美東報價延遲15分鐘
4.36B總市值
47.17本益比TTM

Transmedics Group Inc

127.670
+6.600+5.45%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.45%

5天

+0.69%

1月

-2.49%

6月

+3.33%

今年開始到現在

+104.76%

1年

+106.92%

查看詳細走勢圖

TradingKey Transmedics Group Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Transmedics Group Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名51/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價145.92。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Transmedics Group Inc評分

相關信息

行業排名
51 / 208
全市場排名
134 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 14 分析師
買入
評級
145.917
目標均價
+6.82%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Transmedics Group Inc亮點

亮點風險
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
業績高增長
公司營業收入穩步增長,連續3年增長372.44%
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值47.17,處於3年歷史合理位
機構減倉
最新機構持股37.62M股,環比減少17.85%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉479.00股

Transmedics Group Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Transmedics Group Inc簡介

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
公司代碼TMDX
公司Transmedics Group Inc
CEOHassanein (Waleed H)
網址https://www.transmedics.com/

常見問題

Transmedics Group Inc(TMDX)的當前股價是多少?

Transmedics Group Inc(TMDX)的當前股價是 127.670。

Transmedics Group Inc 的股票代碼是什麼?

Transmedics Group Inc的股票代碼是TMDX。

Transmedics Group Inc股票的52週最高點是多少?

Transmedics Group Inc股票的52週最高點是156.000。

Transmedics Group Inc股票的52週最低點是多少?

Transmedics Group Inc股票的52週最低點是55.000。

Transmedics Group Inc的市值是多少?

Transmedics Group Inc的市值是4.36B。

Transmedics Group Inc的淨利潤是多少?

Transmedics Group Inc的淨利潤為35.46M。

現在Transmedics Group Inc(TMDX)的股票是買入、持有還是賣出?

根據分析師評級,Transmedics Group Inc(TMDX)的總體評級為買入,目標價格為145.917。

Transmedics Group Inc(TMDX)股票的每股收益(EPS TTM)是多少

Transmedics Group Inc(TMDX)股票的每股收益(EPS TTM)是2.707。
KeyAI